VIVO CANNABIS ANNOUNCES APPOINTMENT OF VICE PRESIDENT, NAPANEE OPERATIONS
VIVO CANNABIS ANNOUNCES CANNABIS OIL SALES LICENSE GRANTED TO WHOLLY-OWNED ABCANN MEDICINALS
VIVO CANNABIS ANNOUNCES APPOINTMENT OF DR. RICHA LOVE AS CHIEF MEDICAL OFFICER
VIVO CANNABIS™ RETAINS NATIONAL CAPITAL MARKETS TO PROVIDE INVESTOR RELATIONS SERVICES
VIVO ANNOUNCES APPOINTMENT OF PRESIDENT, EUROPEAN OPERATIONS
CANNA FARMS WINS TOP REVIEWED LICENSED PRODUCER OF THE YEAR AWARD
VIVO Cannabis™ Reports Record Revenue for Q3 2018
Harvest Medicine Launches Free Medical Cannabis Telemedicine Platform
VIVO Announces Initial $5 Million Strategic Investment in National Access Cannabis
Harvest Medicine Continues National Expansion with Acquisition of Trauma Healing Centres
VIVO AND LOYALIST COLLEGE COLLABORATE ON CANNABIS APPLIED RESEARCH PROJECT
VIVO Partners with Pharmascience to Develop Novel Cannabis Products
VIVO Announces $5 million Strategic Investment and Supply Agreement with Westleaf
VIVO selects Green Hedge as Distribution Partner for Adult-Use Products
VIVO Cannabis Inc. Upgrades to the OTCQX Best Market
VIVO Completes First New Seasonal Greenhouse
Canna Farms Completes First Shipment of Recreational Cannabis
VIVO Cannabis Completes Acquisition of Canna Farms
VIVO Cannabis Releases Q2 2018 Results and Provides Business Update
VIVO Cannabis Selected as a Supplier to Ontario Retail Cannabis Market
ABcann Global Announces Company Name Change to VIVO Cannabis™
ABcann Introduces Lumina, a Cannabis Brand Focused on Wellness
Analyst Call re Canna Farms acquisition
ABcann to Acquire Leading B.C. Producer Canna Farms
ABcann Launches FIRESIDE, a Premium Line of Recreational Cannabis
ABcann Selected as a Supplier to Alberta Retail Cannabis Market
Harvest Medicine Surpasses 15,000 Patient Milestone in under 18 Months of Operation
ABcann Global Announces Results of Annual General Meeting
ABcann Launches Beacon Medical
ABcann Provides Business Update
Choom™ and ABcann Announce Strategic Investment and Supply Agreement
ABCANN ANNOUNCES RESIGNATION OF FOUNDING DIRECTOR KEN CLEMENT
ABCANN RETAINS VIRTUE AS AGENCY OF RECORD
ABCANN GLOBAL PROVIDES BUSINESS UPDATE
ABCANN GLOBAL CORPORATION ANNOUNCES FILING OF FINAL PROSPECTUS
ABCANN COMPLETES ACQUISITION OF HARVEST MEDICINE
ABCANN GLOBAL CORPORATION ANNOUNCES $70 MILLION BOUGHT DEAL FINANCING
ABCANN GRANTED AUSTRALIAN IMPORT LICENSE
ABCANN APPOINTS NEW CHIEF MARKETING OFFICER
ABCANN GLOBAL ANNOUNCES RECEIPT OF HEALTH CANADA LICENSE TO PRODUCE CANNABIS OILS
ABcann Enters into Agreement to Acquire Leading Medical Cannabis Clinic
ABcann Global Announces Financial Results and Provides Operational Update
ABcann Global Announces $30 Million Debenture Financing
ABcann Global Strengthens Board and Executive Team
ABcann Global Appoints New Independent Chair
ABcann Global Receives $11.9 Million from Exercise of Warrants
ABcann Global Appoints Barry Fishman as Chief Executive Officer
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
ABcann Global files Q2 2017 Financial Results and Provides Operational Update
Management’s Discussion and Analysis
ABcann RELEASES HIGH LEVEL CBD PRODUCT AND LAUNCHES INITIAL OILS STRATEGY
ABcann GLOBAL PROVIDES CONSTRUCTION AND EXPANSION UPDATE
ABcann GLOBAL ANNOUNCES LISTING ON THE OTCQB MARKETPLACE AND THE FRANKFURT STOCK EXCHANGE
ABcann AND CANNABIS WHEATON ANNOUNCE SIGNING OF AGREEMENT FOR FIRST TRANCHE $15 MILLION INVESTMENT
ABcann GLOBAL ANNOUNCES INCLUSION ON THE HORIZONS MEDICAL MARIJUANA LIFE SCIENCES ETF
ABcann GLOBAL RECRUITS DR. MICHAEL SHANNON AS CHIEF MEDICAL CONSULTANT
ABcann GLOBAL EXTENDS RESEARCH AGREEMENT WITH THE UNIVERSITY OF GUELPH
ABcann GLOBAL ANNOUNCES APPOINTMENT OF W. BRETT WILSON TO ADVISORY BOARD
PANDA AND ABcann MEDICINALS ANNOUNCE MULTI-STAGE PRODUCT TESTING METHODOLOGY
PANDA AND ABcann MEDICINALS ANNOUNCE CONDITIONAL APPROVAL OF QUALIFYING TRANSACTION
PANDA ANNOUNCES PROPOSED QUALIFYING TRANSACTION WITH ABcann MEDICINALS INC